

# Alyssa R Golden

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3251629/publications.pdf>

Version: 2024-02-01

28  
papers

1,454  
citations

516681

16  
h-index

477281

29  
g-index

29  
all docs

29  
docs citations

29  
times ranked

1786  
citing authors

| #  | ARTICLE  | IF   | CITATIONS |
|----|--|------|-----------|
| 1  | Activity of cefepime/taniborbactam and comparators against whole genome sequenced ertapenem-non-susceptible Enterobacterales clinical isolates: CANWARD 2007â€“19. JAC-Antimicrobial Resistance, 2022, 4, dlab197.   | 2.1  | 10        |
| 2  | PCV-15 and PPSV-23 coverage of invasive and respiratory tract <i>Streptococcus pneumoniae</i> , including MDR and XDR isolates: CANWARD 2007â€“20. Journal of Antimicrobial Chemotherapy, 2022, 77, 1444-1451.   | 3.0  | 2         |
| 3  | Sulopenem: An Intravenous and Oral Penem for the Treatment of Urinary Tract Infections Due to Multidrug-Resistant Bacteria. Drugs, 2022, 82, 533-557.  | 10.9 | 12        |
| 4  | Comparison of PCV-10 and PCV-13 vaccine coverage for invasive pneumococcal isolates obtained across Canadian geographic regions, SAVE 2011 to 2017. Diagnostic Microbiology and Infectious Disease, 2021, 99, 115282.  | 1.8  | 7         |
| 5  | Lefamulin: A Novel Oral and Intravenous Pleuromutilin for the Treatment of Community-Acquired Bacterial Pneumonia. Drugs, 2021, 81, 233-256.   | 10.9 | 20        |
| 6  | ESBL-positive <i>Escherichia coli</i> and <i>Klebsiella pneumoniae</i> isolates from across Canada: CANWARD surveillance study, 2007â€“18. Journal of Antimicrobial Chemotherapy, 2021, 76, 2815-2824.   | 3.0  | 8         |
| 7  | Comparison of phenotypic antimicrobial susceptibility testing results and WGS-derived genotypic resistance profiles for a cohort of ESBL-producing <i>Escherichia coli</i> collected from Canadian hospitals: CANWARD 2007â€“18. Journal of Antimicrobial Chemotherapy, 2021, 76, 2825-2832. | 3.0  | 4         |
| 8  | In vitro activity of imipenem-relebactam against various resistance phenotypes/genotypes of Enterobacterales and Pseudomonas aeruginosa isolated from patients across Canada as part of the CANWARD study, 2016-2019. Diagnostic Microbiology and Infectious Disease, 2021, 101, 115418.     | 1.8  | 8         |
| 9  | Whole genome characterization of Streptococcus pneumoniae from respiratory and blood cultures collected from Canadian hospitals before and after PCV-13 implementation in Canada: Focus on serotypes 22F and 33F from CANWARD 2007â€“2018. Vaccine, 2021, 39, 5474-5483.                     | 3.8  | 6         |
| 10 | Use of Fosfomycin Etest To Determine <i>In Vitro</i> Susceptibility of Clinical Isolates of Enterobacterales Other than Escherichia coli, Nonfermenting Gram-Negative Bacilli, and Gram-Positive Cocci. Journal of Clinical Microbiology, 2021, 59, e0163521.                                | 3.9  | 7         |
| 11 | Invasive pneumococcal disease caused by serotypes 22F and 33F in Canada: the SAVE study 2011â€“2018. Diagnostic Microbiology and Infectious Disease, 2021, 101, 115447.  | 1.8  | 7         |
| 12 | Omadacycline: A Novel Oral and Intravenous Aminomethylcycline Antibiotic Agent. Drugs, 2020, 80, 285-313.  | 10.9 | 60        |
| 13 | In Vitro Activity of Cefiderocol, a Novel Siderophore Cephalosporin, against Gram-Negative Bacilli Isolated from Patients in Canadian Intensive Care Units. Diagnostic Microbiology and Infectious Disease, 2020, 97, 115012.  | 1.8  | 36        |
| 14 | Trends in antimicrobial resistance over 10 years among key bacterial pathogens from Canadian hospitals: results of the CANWARD study 2007â€“16. Journal of Antimicrobial Chemotherapy, 2019, 74, iv22-iv31.  | 3.0  | 16        |
| 15 | Comparison of antimicrobial resistance patterns in Streptococcus pneumoniae from respiratory and blood cultures in Canadian hospitals from 2007â€“16. Journal of Antimicrobial Chemotherapy, 2019, 74, iv39-iv47.  | 3.0  | 21        |
| 16 | 42936 pathogens from Canadian hospitals: 10 years of results (2007â€“16) from the CANWARD surveillance study. Journal of Antimicrobial Chemotherapy, 2019, 74, iv5-iv21.   | 3.0  | 43        |
| 17 | Antimicrobial-resistant pathogens in Canadian ICUs: results of the CANWARD 2007 to 2016 study. Journal of Antimicrobial Chemotherapy, 2019, 74, 645-653.   | 3.0  | 26        |
| 18 | Cefiderocol: A Siderophore Cephalosporin with Activity Against Carbapenem-Resistant and Multidrug-Resistant Gram-Negative Bacilli. Drugs, 2019, 79, 271-289.   | 10.9 | 274       |

| #  | ARTICLE   | IF   | CITATIONS |
|----|---|------|-----------|
| 19 | Imipenemâ€“Relebactam and Meropenemâ€“Vaborbactam: Two Novel Carbapenem-Î²-Lactamase Inhibitor Combinations. <i>Drugs</i> , 2018, 78, 65-98.  | 10.9 | 291       |
| 20 | Analysis of multidrug resistance in the predominant <i>Streptococcus pneumoniae</i> serotypes in Canada: the SAVE study, 2011â€“15. <i>Journal of Antimicrobial Chemotherapy</i> , 2018, 73, vii12-vii19.                   | 3.0  | 48        |
| 21 | Molecular characterization of predominant <i>Streptococcus pneumoniae</i> serotypes causing invasive infections in Canada: the SAVE study, 2011â€“15. <i>Journal of Antimicrobial Chemotherapy</i> , 2018, 73, vii20-vii31. | 3.0  | 27        |
| 22 | Antimicrobial susceptibility testing of invasive isolates of <i>Streptococcus pneumoniae</i> from Canadian patients: the SAVE study, 2011â€“15. <i>Journal of Antimicrobial Chemotherapy</i> , 2018, 73, vii5-vii11.        | 3.0  | 17        |
| 23 | Solithromycin: A Novel Fluoroketolide for the Treatment of Community-Acquired Bacterial Pneumonia. <i>Drugs</i> , 2016, 76, 1737-1757.  | 10.9 | 38        |
| 24 | Invasive <i>Streptococcus pneumoniae</i> in Canada, 2011â€“2014: Characterization of new candidate 15-valent pneumococcal conjugate vaccine serotypes 22F and 33F. <i>Vaccine</i> , 2016, 34, 2527-2530.                    | 3.8  | 28        |
| 25 | Review of Eravacycline, a Novel Fluorocycline Antibacterial Agent. <i>Drugs</i> , 2016, 76, 567-588.  | 10.9 | 199       |
| 26 | Tedizolid: A Novel Oxazolidinone with Potent Activity Against Multidrug-Resistant Gram-Positive Pathogens. <i>Drugs</i> , 2015, 75, 253-270.  | 10.9 | 140       |
| 27 | Assessment of multidrug resistance, clonality and virulence in non-PCV-13 <i>Streptococcus pneumoniae</i> serotypes in Canada, 2011-13. <i>Journal of Antimicrobial Chemotherapy</i> , 2015, 70, 1960-4.                    | 3.0  | 31        |
| 28 | Characterization of MDR and XDR <i>Streptococcus pneumoniae</i> in Canada, 2007â€“13. <i>Journal of Antimicrobial Chemotherapy</i> , 2015, 70, 2199-2202.   | 3.0  | 65        |